Welcome to CSNpharm! For Research Use Only!

β-catenin

β-catenin

Cat. No. Product Name CAS No. Information
CSN27594 β-catenin-IN-2 1458664-10-2 β-catenin-IN-2 is a potent β-catenin inhibitor that can be used for the study of colorectal cancer.
CSN17476 WAY-262611   1123231-07-1 WAY-262611 is an agonist of -Catenin and can increase bone formation rate with EC50 of 063 M
CSN19412 Triptonide 38647-11-9 Triptonide, a natural product isolated and purified from the herb of Tripterygium wilfordii Hook.f. with antileukemic, antitumor, anti-inflammatory activities, is effective in the treatment of autoimmune diseases. Triptonide can effectively inhibit canonical Wnt/β-catenin signaling by targeting the downstream C-terminal transcription domain of β-catenin or a nuclear component associated with β-catenin.
CSN19245 SKL2001   909089-13-0 SKL2001 is Wnt-catenin pathway agonist which interferes in the interaction of Axin-catenin
CSN20164 PP2A-β-Catenin Inhibitor CS-11 N/A PP2A--Catenin inhibitor CS-11 a small molecule inhibitor of PP2A--catenin signaling that limits both in vivo tumor growth and metastasis
CSN11650 Pamidronic acid   40391-99-9 Pamidronic Acid is a an amino- bisphosphonate used to prevent bone loss and treat osteoporosis.
CSN33101 NRX-103094 2763260-36-0 NRX-103094, a molecular glue, is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-103094 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 62 nM and a Kd of 0.6 nM.
CSN20582 KY1220 292168-79-7 KY1220 inhibits Wnt-catenin pathway with IC50 of 21 M in HEK293 cells and it can destabilize both -catenin and Ras
CSN12696 ICG001 868774-16-7 ICG-001 is an inhibitor of β-catenin/cyclic AMP responsive element binding protein binding protein (CBP)-mediated transcription with IC50 of 3 µM.
CSN22363 C-82 1422253-37-9 C-82 is an active metabolite of PRI-724 which selectively inhibits the CBP-catenin interaction
CSN20163 Tegatrabetan 1227637-23-1 beta-Catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma
<< PREV 1 NEXT >>